Get the Stockscreener App
4.59
4.18%
-0.20
Foghorn Therapeutics Inc stock is traded at $4.59, with a volume of 160.87K.
It is down -4.18% in the last 24 hours and down -16.39% over the past month.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
See More
Previous Close:
$4.79
Open:
$4.78
24h Volume:
160.87K
Relative Volume:
0.92
Market Cap:
$269.43M
Revenue:
$30.91M
Net Income/Loss:
$-74.28M
P/E Ratio:
-3.7675
EPS:
-1.2183
Net Cash Flow:
$-86.15M
1W Performance:
-6.90%
1M Performance:
-16.39%
6M Performance:
+13.05%
1Y Performance:
+42.11%
1-Day Range:
$4.525
$4.78
1-Week Range:
$4.525
$5.20
52-Week Range:
$3.14
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.59 | 269.43M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
436.27 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
748.87 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
799.65 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.11 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.66 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Resumed | Jefferies | Buy |
| Dec-18-25 | Initiated | BTIG Research | Buy |
| Nov-07-25 | Initiated | Guggenheim | Buy |
| Sep-17-25 | Resumed | B. Riley Securities | Buy |
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
If You Invested $1,000 in Foghorn Therapeutics Inc. (FHTX) - Stock Titan
Trading Recap: Can Foghorn Therapeutics Inc weather a recession2026 Spike Watch & Technical Pattern Recognition Alerts - baoquankhu1.vn
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting - Investing News Network
Foghorn to present preclinical cancer data at AACR meeting By Investing.com - Investing.com South Africa
Foghorn Therapeutics details preclinical advances across oncology programs - Traders Union
Foghorn to present preclinical cancer data at AACR meeting - Investing.com
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor ... - Bluefield Daily Telegraph
New lung, breast and blood cancer data put Foghorn programs at AACR - Stock Titan
Strength seen in Dianthus Therapeutics, Inc. (DNTH): Can its 5.6% jump turn into more strength? - MSN
FHTX PE Ratio & Valuation, Is FHTX Overvalued - Intellectia AI
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
FHTX Technical Analysis & Stock Price Forecast - Intellectia AI
FHTX Stock Price, Quote & Chart | FOGHORN THERAPEUTICS INC (NASDAQ:FHTX) - ChartMill
Strength Observed in Dianthus Therapeutics, Inc. (DNTH): Will Its 5.6% Increase Lead to Further Gains? - Bitget
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength? - Yahoo! Finance Canada
FHTX Should I Buy - Intellectia AI
Aug Final Week: Can Foghorn Therapeutics Inc weather a recessionCPI Data & High Conviction Investment Ideas - baoquankhu1.vn
Setup Watch: Is Foghorn Therapeutics Inc part of any major index2026 Price Action Summary & Consistent Profit Trading Strategies - baoquankhu1.vn
Contrasting Foghorn Therapeutics (NASDAQ:FHTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
Fundamentals Check: Is Foghorn Therapeutics Inc stock a good dividend stock2026 Earnings Impact & Daily Profit Focused Stock Screening - baoquankhu1.vn
Ideas Watch: Is Foghorn Therapeutics Inc stock a hidden gem2026 Fundamental Recap & Safe Entry Point Identification - baoquankhu1.vn
Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress By Investing.com - Investing.com Canada
What is HC Wainwright's Forecast for FHTX FY2026 Earnings? - MarketBeat
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
FY2030 Earnings Estimate for FHTX Issued By HC Wainwright - Defense World
Brokers Offer Predictions for FHTX FY2030 Earnings - MarketBeat
Foghorn Therapeutics (FHTX) Receives a Buy from Guggenheim - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Tenax Therapeutics (TENX), RegenXBio (RGNX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - simplywall.st
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com India
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Foghorn Therapeutics (NASDAQ:FHTX) Earns "Outperform" Rating from Wedbush - MarketBeat
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - Bitget
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics (FHTX) maps chromatin-targeting cancer pipeline with Lilly - Stock Titan
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Cancer drug developer Foghorn raises $50M, funds work on hard-to-treat tumors - Stock Titan
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
3.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):